<DOC>
	<DOCNO>NCT01769391</DOCNO>
	<brief_summary>The main purpose study evaluate necitumumab added standard chemotherapy paclitaxel carboplatin effective treat cancer standard chemotherapy paclitaxel carboplatin alone .</brief_summary>
	<brief_title>A Study Necitumumab Chemotherapy Participants With Stage IV Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm squamous NSCLC Stage IV disease time study entry base American Joint Committee Cancer ( AJCC ) 7th edition Measurable disease time study entry define Response Evaluation Criteria Solid Tumors , ( RECIST ) Version 1.1 Archived recent tumor tissue ( minimum 5 unstained tissue slide paraffinembedded tissue block ) available analysis epidermal growth factor receptor ( EGFR ) protein expression immunohistochemistry ( IHC ) biomarker assessment Nonsquamous NSCLC Prior anticancer therapy monoclonal antibody , signal transduction inhibitor , therapy target EGFR , vascular endothelial growth factor ( VEGF ) , VEGF receptor Previous chemotherapy NSCLC Major surgery receive investigational therapy 4 week prior randomization Chest irradiation within 12 week prior randomization ( except palliative irradiation bone lesion , allow ) Brain metastasis symptomatic require ongoing treatment steroid anticonvulsant ( Participants undergone previous radiotherapy brain metastasis , nonsymptomatic long require treatment steroid anticonvulsant , eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
</DOC>